文献速递细胞病理与分子病理神经与头颈病理

改良方案对唾液腺SUMP亚分类的多机构验证

Multi-institutional validation of a modified scheme for subcategorizing salivary gland neoplasm of uncertain malignant potential (SUMP).
PubMed 文献 · Cancer Cytopathol · 2022-05-30

该研究回顾10家机构9938例唾液腺细针穿刺,其中742例(7.5%)归为SUMP,329例可复核并亚分类。嗜酸细胞/嗜酸样SUMP的恶性风险(52.5%)显著高于基底样SUMP(36.5%,P=.0142)和SUMP NOS(31.9%,P=.0084)。

要点

  • SUMP总体恶性风险为40.4%,亚分类可区分风险。
  • 嗜酸细胞/嗜酸样SUMP恶性风险最高(52.5%)。
  • 基质或背景类型(B1/B2、O1/O2)间恶性风险无显著差异。

核心结论

  • 嗜酸细胞/嗜酸样SUMP的恶性风险为52.5%,显著高于基底样SUMP(36.5%,P=.0142)和SUMP NOS(31.9%,P=.0084)。
  • 不同细胞外基质或背景物质类型之间恶性风险无显著差异。

研究设计与样本

  • 回顾性多机构研究,纳入10家机构连续9938例唾液腺细针穿刺,按米兰系统分类。
  • 742例(7.5%)诊断为SUMP,其中525例(70.8%)有手术随访,329例(62.7%)有细胞学玻片可供复核。
  • 按改良方案亚分类为基底样SUMP(B1/B2)、嗜酸细胞/嗜酸样SUMP(O1/O2)和SUMP NOS。

主要发现

  • SUMP总体恶性风险为40.4%。
  • 基底样SUMP 156例(47.4%),恶性风险36.5%。
  • 嗜酸细胞/嗜酸样SUMP 101例(30.7%),恶性风险52.5%。
  • SUMP NOS 72例(21.9%),恶性风险31.9%。
  • B1与B2恶性风险分别为36.7%与36.4%(P=1.0000),O1与O2分别为65.2%与48.7%(P=.2349)。

关键数值与推荐

  • 基底样SUMP:B1为非纤维性基质缺失/稀少,B2为非纤维性或混合型基质存在。
  • 嗜酸细胞/嗜酸样SUMP:O1伴黏液背景,O2不伴黏液背景。
  • 嗜酸细胞/嗜酸样SUMP恶性风险显著高于基底样SUMP(P=.0142)和SUMP NOS(P=.0084)。
  • B1与B2、O1与O2之间恶性风险无显著差异(P=1.0000和P=.2349)。

临床怎么用

  • 对SUMP进行亚分类有助于分层恶性风险,嗜酸细胞/嗜酸样亚类风险较高。
  • 基质或背景特征(B1/B2、O1/O2)对风险分层价值有限。

局限性

  • 回顾性研究设计。
  • 仅329例(62.7%)SUMP有细胞学玻片可供复核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The salivary gland neoplasm of uncertain malignant potential (SUMP) category in the Milan System is diagnostically challenging. This study aims to validate a modified scheme for subcategorizing SUMP in a large multi-institutional cohort. METHODS: Retrospective review of salivary gland fine-needle aspirations (FNAs) from 10 institutions were classified based on the Milan System. Cases diagnosed as SUMP with available cytology slides and surgical follow-up were retrieved for review and subcategorized based on a modified scheme as follows: basaloid SUMP (B1: absent/scant nonfibrillary matrix; B2: presence of nonfibrillary/mixed-type matrix), oncocytic/oncocytoid SUMP (O1: with mucinous background; O2: without mucinous background), and SUMP not otherwise specified (NOS). RESULTS: A total of 742 (7.5%) cases from 9938 consecutive salivary gland FNAs were classified as SUMP. Among them, 525 (70.8%) had surgical follow-up and 329 (62.7%) were available for review. The overall risk of malignancy (ROM) of SUMP was 40.4%. There were 156 cases (47.4%) subcategorized as basaloid SUMP with a ROM of 36.5%, 101 (30.7%) as oncocytic/oncocytoid SUMP with a ROM of 52.5%, and 72 (21.9%) as SUMP NOS with a ROM of 31.9%. The ROM of oncocytic/oncocytoid SUMP was significantly higher than basaloid SUMP (P = .0142) and SUMP NOS (P = .0084). No significant differences in ROM were noted between B1 and B2 (36.7% vs 36.4%, P = 1.0000) and O1 and O2 (65.2% vs 48.7%, P = .2349). CONCLUSIONS: The ROM of oncocytic/oncocytoid SUMP was 52.5% and significantly higher than that of basaloid SUMP (36.5%, P = .0142) and SUMP NOS (31.9%, P = .0084), whereas no significant differences in ROM were noted for cases with different types of extracellular matrix or background material.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Hang JF, Lee JJL, Nga ME, et al. Multi-institutional validation of a modified scheme for subcategorizing salivary gland neoplasm of uncertain malignant potential (SUMP). Cancer Cytopathol. 2022. PMID: 35637575. doi:10.1002/cncy.22593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。